Therapeutic Areas

Latest News

Credit: mi_viri | stock.adobe.com
EMPA-KIDNEY Trial Shows Jardiance Reduces Chronic Kidney Disease Progression, Cardiovascular Death Risk, with Benefits Lasting Up to One Year Post-Treatment

October 30th 2024

EMPA-KIDNEY trial shows that two years of treatment with Jardiance (empagliflozin) significantly lowered the risk of chronic kidney disease progression and cardiovascular death, with lasting cardiorenal benefits up to one year after treatment ended.

Credit: Uladzislau | stock.adobe.com
Tremfya Achieves Significant Clinical Remission, Endoscopic Response in Moderate to Severe Crohn Disease at 48 Weeks

October 29th 2024

Credit: antkevyv | stock.adobe.com
Omvoh Achieves Long-Term Remission, Symptom Improvement for Ulcerative Colitis, Crohn Disease in Phase III Trials

October 28th 2024

Credit: ltyuan | stock.adobe.com
Ebglyss Shows Significant Improvement in Skin Symptoms, Itch for Moderate-to-Severe Atopic Dermatitis

October 25th 2024

Credit: Julia | stock.adobe.com
RSV Vaccine Arexvy Shows Potential for Expanded Use in At-Risk Adults Aged 18-49, Including Immunocompromised

October 24th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.